copper assay raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-13 and is reviewed periodically as new material appears.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) tripeptide complex | Contains glycyl-histidyl-lysine ligand |
| Peptide sequence | Gly-His-Lys | N-terminal glycine, C-terminal lysine |
| Molecular formula | C14H22CuN6O4 | Commonly cited for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility | Water-soluble | Also dissolves in some polar solvents |
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
The production was noted (by Nehad Selaiha of the weekly Al-Ahram) not only for its unexpected change of plot at the very end but also for its chorus of one hundred who alternated their speech between Arabic and English. The translation used was that of George Theodoridis. US Latina playwright Caridad Svich's 2009 play Wreckage, which premiered at Crowded Fire Theatre in San Francisco, tells the story of Medea from the sons' point of view, in the afterlife. Paperstrangers Performance Group toured a critically acclaimed production of Medea directed by Michael Burke to U.S. Fringe Festivals in 2009 and 2010. Bart Lee's interpretation of Medea, renamed Medea, My Dear, was performed in Surrey and later toured the south of England from 2010 to 2011. Luis Alfaro's re-imagining of Medea, Mojada, world premiered at Victory Gardens Theater in 2013. Theatre Lab's production, by Greek director Anastasia Revi, opened at The Riverside Studios, London, on 5 March 2014. The Hungry Woman: A Mexican Medea by Cherríe Moraga takes elements of Medea and of other works. 14 July – 4 September 2014 London Royal National Theatre staging of Euripides in a new version by Ben Power, starring Helen McCrory as Medea, directed by Carrie Cracknell, music by Will Gregory and Alison Goldfrapp. 25 September – 14 November 2015 London Almeida Theatre a new adaptation by Rachel Cusk, starring Kate Fleetwood as Medea, directed by Rupert Goold. 17 February – 6 March 2016 in Austin at the Long Center for the Performing Arts starring Franchelle Stewart Dorn as Medea and directed by Ann Ciccolella.
=== Kla Tham Party === Deputy Prime Minister Thamanat Prompow first noted that the results exceeded expectations, especially in northern Thailand. He remained confident that the party would surpass more than 50 seats, emphasizing how the ministers and candidates of the Kla Tham Party were actively working in their respective constituencies throughout the campaign. Thamanat remarked that the party was still waiting for an invitation from Bhumjaithai to renew their past coalition. The party finished with 58 seats, ahead of his forecast, but no invitation came and Kla Tham was left out of the government.
== Decay == Uranium-238 is an alpha emitter, producing thorium-234 which is a beta emitter, etc. This leads to a decay chain, commonly called the radium series or uranium series. Beginning with naturally occurring uranium-238, this series includes isotopes of astatine, bismuth, lead, polonium, protactinium, radium, radon, thallium, thorium and uranium, all of which are present in natural uranium sources. The decay proceeds as (only main decay branches shown):
== Other uses == VIP style, or VIP Car, a car modification trend Plymouth VIP, a luxury version of the Plymouth Fury (1966-1969) Vacuum insulated panel, a form of thermal insulation consisting of a nearly gas-tight enclosure surrounding a rigid core, from which the air has been evacuated Variable Information Printing, a form of on-demand printing VimpelCom, a stock symbol VIP Ecuador, an Ecuadorian airline VIP Industries, a luggage manufacturer based in India VIP's (restaurant), an American restaurant chain Virgil Partch, a cartoonist who signed his work Vip Virgin Islands Party, a political party in the British Virgin Islands Virology Science and Technology Institute of the Philippines, also known as the Virology Institute of the Philippines (VIP) Vision Inspired by the People, a political party in Belize Visually impaired person, a person with a decreased ability to see
There are several causes of hyperthyroidism. Most often, the entire gland is overproducing thyroid hormone. Less commonly, a single nodule is responsible for the excess hormone secretion, called a "hot" nodule. Thyroiditis (inflammation of the thyroid) can also cause hyperthyroidism. Functional thyroid tissue producing an excess of thyroid hormone occurs in a number of clinical conditions. The major causes in humans are:
Sources: en.wikipedia.org
Silver staining is the use of silver to stain histologic sections. This kind of staining is important in the demonstration of proteins (for example type III collagen) and DNA. It is used to show both substances inside and outside cells. Silver staining is also used in temperature gradient gel electrophoresis. Argentaffin cells reduce silver solution to metallic silver after formalin fixation. This method was discovered by Italian Camillo Golgi, by using a reaction between silver nitrate and potassium dichromate, thus precipitating silver chromate in some cells (see Golgi's method). Argyrophilic cells reduce silver solution to metallic silver after being exposed to the stain that contains a reductant. An example of this would be hydroquinone or formalin.
Takaki's theory, while incorrectly focusing on macronutrients, was a step in the right direction that resulted in correct treatment. However, keen-eyed observers were able to easily rebut Takaki's theories with counterexamples, so nutritional theories remained heterodox science. In 1897, Christiaan Eijkman, a Dutch physician and pathologist, published his mid-1880s experiments showing that feeding unpolished rice (instead of the polished variety) to chickens helped to prevent beriberi. This was the first experiment to show that not a major chemical, but some minor nutrient, was the true cause of beriberi. The following year, Sir Frederick Hopkins postulated that some foods contained "accessory factors"—in addition to proteins, carbohydrates, fats, and salt—that were necessary for the functions of the human body. In 1901, Gerrit Grijns, a Dutch physician and assistant to Christiaan Eijkman in the Netherlands, correctly interpreted beriberi as a deficiency syndrome, and between 1910 and 1913, Edward Bright Vedder established that an extract of rice bran is a treatment for beriberi. In 1929, Eijkman and Hopkins were awarded the Nobel Prize for Physiology or Medicine for their discoveries. In 1935, Robert R. Williams isolated and cheaply synthesized thiamine from rice bran, based on discoveries he had made as a researcher in Manila's Bureau of Science in 1910. Williams assigned the patents to a fund that worked to promote thiamine-enriched rice in Asia, and in Bataan in particular.
=== Identification of the encoding gene === In 1949, a non-obese mouse colony being studied at the Jackson Laboratory produced a strain of obese offspring, suggesting that a mutation had occurred in a hormone regulating hunger and energy expenditure. Mice homozygous for the so-called ob mutation (ob/ob) ate voraciously and were massively obese. In the 1960s, a second mutation causing obesity and a similar phenotype was identified by Douglas Coleman, also at the Jackson Laboratory, and was named diabetes (db), as both ob/ob and db/db were obese. In 1990 Rudolph Leibel and Jeffrey M. Friedman reported mapping of the db gene. Consistent with Coleman's and Leibel's hypothesis, several subsequent studies from Leibel's and Friedman's labs and other groups confirmed that the ob gene encoded a novel hormone that circulated in blood and that could suppress food intake and body weight in ob and wild type mice, but not in db mice. In 1994, Friedman's laboratory reported the identification of the gene. In 1995, Jose F. Caro's laboratory provided evidence that the mutations in the mouse ob gene did not occur in humans. Furthermore, since ob gene expression was increased, not decreased, in human obesity, it suggested resistance to leptin to be a possibility. At the suggestion of Roger Guillemin, Friedman named this new hormone "leptin" from the Greek lepto meaning thin. Leptin was the first fat cell-derived hormone (adipokine) to be discovered.
=== Christmas Island Phosphate Company === The first European to recommend mining of phosphate for commercial exploitation was Sir John Murray, a British naturalist, during the 1872–76 Challenger expedition. His discovery led to annexation of the island by the British Crown on 6 June 1888. In 1900 the Pacific Islands Company Ltd commenced mining on Ocean Island, with 1550 tons shipped from September to December 1901 and 13,350 tons in the following year. John T. Arundel and Lord Stanmore, directors of PIC, were responsible for financing the new opportunities and negotiating with the German company that controlled the licences to mine in Nauru. In 1902 the interests of PIC were merged with Jaluit Gesellschaft of Hamburg, to form the Pacific Phosphate Company Ltd (PPC), to engage in phosphate mining in Nauru and Ocean Island.
Sources: en.wikipedia.org
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.
Yes, it is found in human plasma, saliva, and urine. Its concentration in plasma tends to decrease with age. This natural presence is one reason researchers have investigated its role in tissue maintenance.
No, GHK-Cu is not an approved drug in major markets. It is widely used as a cosmetic ingredient, where it is listed under names such as copper tripeptide-1. Any therapeutic claims would require separate regulatory review.
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.